György Nagy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7754616/publications.pdf

Version: 2024-02-01

		101543	58581
130	7,288	36	82
papers	citations	h-index	g-index
122	122	122	12502
133	133	133	13583
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Response to: â€ [*] Correspondence on â€ [*] EULAR definition of difficult-to-treat rheumatoid arthritisâ€ [™] â€ [™] by Novella-Navarro <i>et al</i> . Annals of the Rheumatic Diseases, 2023, 82, e56-e56.	0.9	2
2	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, 20-33.	0.9	104
3	Janus Kinase Inhibitors Improve Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 24,135 Patients. International Journal of Molecular Sciences, 2022, 23, 1246.	4.1	20
4	COVID-19: autoimmunity, multisystemic inflammation and autoimmune rheumatic patients. Expert Reviews in Molecular Medicine, 2022, 24, e13.	3.9	12
5	Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox. Biomedicines, 2022, 10, 434.	3.2	5
6	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET. Clinical and Experimental Rheumatology, 2022, 40, 3-11.	0.8	12
7	Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search. Rheumatology, 2022, 61, 3552-3566.	1.9	19
8	Comorbidities or extra-articular manifestations: time to reconsider the terminology?. Rheumatology, 2022, 61, 3881-3883.	1.9	6
9	Off-label use of mycophenolate mofetil in the treatment of rare and complex rheumatic connective tissue diseases Clinical and Experimental Rheumatology, 2022, , .	0.8	O
10	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET Clinical and Experimental Rheumatology, 2022, , .	0.8	0
11	Activated polymorphonuclear derived extracellular vesicles are potential biomarkers of periprosthetic joint infection. PLoS ONE, 2022, 17, e0268076.	2.5	2
12	Rare clinical manifestations in systemic lupus erythematosus: a review on frequency and clinical presentation. Clinical and Experimental Rheumatology, 2022, 40, 93-102.	0.8	5
13	Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT study. Rheumatology Advances in Practice, 2022, 6, .	0.7	1
14	The associations of long-COVID symptoms, clinical characteristics and affective psychological constructs in a non-hospitalized cohort. Physiology International, 2022, 109, 230-245.	1.6	7
15	High risk of depression, anxiety, and an unfavorable complex comorbidity profile is associated with SLE: a nationwide patient-level study. Arthritis Research and Therapy, 2022, 24, 116.	3.5	3
16	Synovial fibroblasts as potential drug targets in rheumatoid arthritis, where do we stand and where shall we go?. Annals of the Rheumatic Diseases, 2022, 81, 1055-1064.	0.9	29
17	EULAR definition of difficult-to-treat rheumatoid arthritis. Annals of the Rheumatic Diseases, 2021, 80, 31-35.	0.9	224
18	Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open, 2021, 7, e001512.	3.8	42

#	Article	IF	Citations
19	Impact of Medium-Sized Extracellular Vesicles on the Transduction Efficiency of Adeno-Associated Viruses in Neuronal and Primary Astrocyte Cell Cultures. International Journal of Molecular Sciences, 2021, 22, 4221.	4.1	3
20	Preclinical models of arthritis for studying immunotherapy and immune tolerance. Annals of the Rheumatic Diseases, 2021, 80, 1268-1277.	0.9	20
21	Formation of a protein corona on the surface of extracellular vesicles in blood plasma. Journal of Extracellular Vesicles, 2021, 10, e12140.	12.2	150
22	Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open, 2021, 7, e001511.	3.8	12
23	Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline. Frontiers in Pharmacology, 2021, 12, 778649.	3.5	9
24	Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus. Rheumatology, 2020, 59, 3443-3451.	1.9	40
25	Reduced miR-26b Expression in Megakaryocytes and Platelets Contributes to Elevated Level of Platelet Activation Status in Sepsis. International Journal of Molecular Sciences, 2020, 21, 866.	4.1	30
26	Largely Accelerated Arterial Aging in Rheumatoid Arthritis Is Associated With Inflammatory Activity and Smoking in the Early Stage of the Disease. Frontiers in Pharmacology, 2020, 11, 523962.	3.5	12
27	Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. Autoimmunity Reviews, 2019, 18, 102398.	5.8	75
28	P027â€Src-like adaptor protein expression in rheumatoid arthritis. , 2019, , .		0
29	THU0577â€EFFICACY OF RADIOSYNOVIORTHESIS IN PIGMENTED VILLONODULAR SYNOVITIS OF THE KNEE.	, 2019,	0
30	Mechanisms of vascular comorbidity in autoimmune diseases. Current Opinion in Rheumatology, 2018, 30, 197-206.	4.3	12
31	OP0139â€Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. , 2018, , .		0
32	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmunity Reviews, 2018, 17, 1153-1168.	5.8	62
33	Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Annals of the Rheumatic Diseases, 2018, 77, 1705-1709.	0.9	83
34	Distinct In Vitro T-Helper 17 Differentiation Capacity of Peripheral Naive T Cells in Rheumatoid and Psoriatic Arthritis. Frontiers in Immunology, 2018, 9, 606.	4.8	12
35	Affinity Purification and Comparative Biosensor Analysis of Citrulline-Peptide-Specific Antibodies in Rheumatoid Arthritis. International Journal of Molecular Sciences, 2018, 19, 326.	4.1	8
36	Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities?. Autoimmunity Reviews, 2018, 17, 739-745.	5.8	26

#	Article	IF	Citations
37	AB0269â€Ankle synovitis and treat-to-target strategy in clinically and serologically different forms of rheumatoid arthritis, a single-centre experience. , 2018, , .		0
38	Induction and Differentiation of IL-10–Producing Regulatory B Cells from Healthy Blood Donors and Rheumatoid Arthritis Patients. Journal of Immunology, 2017, 198, 1512-1520.	0.8	117
39	Extracellular vesicles regulate the human osteoclastogenesis: divergent roles in discrete inflammatory arthropathies. Cellular and Molecular Life Sciences, 2017, 74, 3599-3611.	5.4	44
40	Biomarkers for rheumatoid arthritis: From molecular processes to diagnostic applications-current concepts and future perspectives. Immunology Letters, 2017, 189, 13-18.	2.5	47
41	Monocyte activation drives preservation of membrane thiols by promoting release of oxidised membrane moieties via extracellular vesicles. Free Radical Biology and Medicine, 2017, 108, 56-65.	2.9	17
42	03.10â€Regulation of the th17 cell differentiation in rheumatoid arthritis. , 2017, , .		0
43	08.06â€Circulating exosomes play a role in the regulation of human in vitro osteoclastogenesis. , 2017, ,		0
44	AB0023â€The Regulation of Human In Vitro Th17 Cell Differentiation by Cytokines. Annals of the Rheumatic Diseases, 2016, 75, 904.3-905.	0.9	0
45	A7.21â€The effect of extracellular vesicles on human <i>in vitro</i> osteoclastogenesis. Annals of the Rheumatic Diseases, 2016, 75, A64.2-A64.	0.9	0
46	A2.18â€Induction and characterisation of the dominant IL-10 producing B cell subset in healthy blood donors and rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2016, 75, A22.2-A22.	0.9	0
47	A2.27â€Affinity measurements of anti-citrullinated protein/peptide antibodies in sera of rheumatoid arthritis patients by applying biosensor analysis. Annals of the Rheumatic Diseases, 2016, 75, A26.1-A26.	0.9	0
48	In vitro eradication of citrullinated protein specific B-lymphocytes of rheumatoid arthritis patients by targeted bifunctional nanoparticles. Arthritis Research and Therapy, 2016, 18, 15.	3.5	20
49	The emerging role of aryl hydrocarbon receptor in the activation and differentiation of Th17 cells. Cellular and Molecular Life Sciences, 2016, 73, 95-117.	5.4	43
50	A2.39â€Cytokine-induced regulation of human TH17 differentiation. Annals of the Rheumatic Diseases, 2016, 75, A31.1-A31.	0.9	0
51	SPO241â€Extracellular Vesicles in Rheumatic Diseases. Annals of the Rheumatic Diseases, 2015, 74, 58.4-59.	0.9	0
52	Inflammatory Mediators in Autoimmunity and Systemic Autoimmune Diseases. Mediators of Inflammation, 2015, 2015, 1-2.	3.0	3
53	Isolation of Exosomes from Blood Plasma: Qualitative and Quantitative Comparison of Ultracentrifugation and Size Exclusion Chromatography Methods. PLoS ONE, 2015, 10, e0145686.	2.5	493
54	The Emerging and Diverse Roles of Src-Like Adaptor Proteins in Health and Disease. Mediators of Inflammation, 2015, 2015, 1-9.	3.0	11

#	Article	IF	CITATIONS
55	Selected Aspects in the Pathogenesis of Autoimmune Diseases. Mediators of Inflammation, 2015, 2015, 1-11.	3.0	31
56	A1.7â€The regulation of human in vitro TH17 cell differentiation. Annals of the Rheumatic Diseases, 2015, 74, A3.1-A3.	0.9	0
57	A1.15â€Rheumatoid arthritis patients possess a reduced number of IL-10 producing CD27+regulatory B cells. Annals of the Rheumatic Diseases, 2015, 74, A6.2-A7.	0.9	0
58	Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?. Arthritis Research and Therapy, 2015, 17, 181.	3.5	59
59	TGFÎ ² Activated Kinase 1 (TAK1) at the Crossroad of B Cell Receptor and Toll-Like Receptor 9 Signaling Pathways in Human B Cells. PLoS ONE, 2014, 9, e96381.	2.5	16
60	Suppression of innate and adaptive B cell activation pathways by antibody coengagement of Fc \hat{I}^3 RIIb and CD19. MAbs, 2014, 6, 991-999.	5.2	28
61	A8.7â€Differentiation of human TH17 cells. Annals of the Rheumatic Diseases, 2014, 73, A78.3-A79.	0.9	0
62	Recognition of new citrullineâ€containing peptide epitopes by autoantibodies produced <i>in vivo</i> and <i>in vitro</i> by B cells of rheumatoid arthritis patients. Immunology, 2014, 141, 181-191.	4.4	22
63	Emerging role of extracellular vesicles in inflammatory diseases. Nature Reviews Rheumatology, 2014, 10, 356-364.	8.0	563
64	Early start and stop of biologics: has the time come?. BMC Medicine, 2014, 12, 25.	5.5	22
65	Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. European Journal of Health Economics, 2014, 15, 53-64.	2.8	26
66	A8.22â€The role of proinflammatory and anti-inflammatory cytokines on CD3ζ-chain expression of human T- lymphocytes. Annals of the Rheumatic Diseases, 2014, 73, A85.1-A85.	0.9	0
67	Bead Arrays for Antibody and Complement Profiling Reveal Joint Contribution of Antibody Isotypes to C3 Deposition. PLoS ONE, 2014, 9, e96403.	2.5	13
68	Oxidative Stress in Rheumatoid Arthritis. , 2013, , 145-167.		8
69	The role of citrullination of an immunodominant proteoglycan (PG) aggrecan T cell epitope in BALB/c mice with PG-induced arthritis. Immunology Letters, 2013, 152, 25-31.	2.5	10
70	The recently identified hexosaminidase D enzyme substantially contributes to the elevated hexosaminidase activity in rheumatoid arthritis. Immunology Letters, 2013, 149, 71-76.	2.5	25
71	Role of <i>N</i> - or <i>C</i> -Terminal Biotinylation in Autoantibody Recognition of Citrullin Containing Filaggrin Epitope Peptides in Rheumatoid Arthritis. Bioconjugate Chemistry, 2013, 24, 817-827.	3.6	12
72	Antibacterial effect of microvesicles released from human neutrophilic granulocytes. Blood, 2013, 121, 510-518.	1.4	185

#	Article	lF	CITATIONS
73	A3.20â€TNF Regulates CD3ζ Expression of T Lymphocytes Via SRC-Like Adaptor Protein-Dependent Proteasomal Degradation. Annals of the Rheumatic Diseases, 2013, 72, A20.3-A21.	0.9	O
74	A5.23â€Multiparameter Phospho-Flow Analysis of B Cells from Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A38.3-A39.	0.9	0
75	A7.4â€Association of Galectin Single Nucleotide Polymorphisms with Autoimmune Diseases. Annals of the Rheumatic Diseases, 2013, 72, A49.1-A49.	0.9	0
76	A novel flow cytometric approach reveals abundant CD8+ T cell derived microvesicles in rheumatoid arthritis synovial fluid samples. Annals of the Rheumatic Diseases, 2012, 71, A19.2-A19.	0.9	3
77	Who are the young professionals working in the field of rheumatology in Europe and what are their needs? An EMEUNET (EMerging EUlar NETwork) survey. Annals of the Rheumatic Diseases, 2012, 71, 1432-1433.	0.9	10
78	Citrullination under physiological and pathological conditions. Joint Bone Spine, 2012, 79, 431-436.	1.6	107
79	Non-synonymous single nucleotide polymorphisms in genes for immunoregulatory galectins: Association of galectin-8 (F19Y) occurrence with autoimmune diseases in a Caucasian population. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 1512-1518.	2.4	28
80	Improved Flow Cytometric Assessment Reveals Distinct Microvesicle (Cell-Derived Microparticle) Signatures in Joint Diseases. PLoS ONE, 2012, 7, e49726.	2.5	129
81	CD3ζ-Chain Expression of Human T Lymphocytes Is Regulated by TNF via Src-like Adaptor Protein-Dependent Proteasomal Degradation. Journal of Immunology, 2012, 189, 1602-1610.	0.8	35
82	CD3ζ-chain expression is regulated by tumor necrosis factor via Src-like adaptor protein dependent proteosomal degradation in human T lymphocytes. Annals of the Rheumatic Diseases, 2012, 71, A1.3-A2.	0.9	0
83	Detection and isolation of cell-derived microparticles are compromised by protein complexes resulting from shared biophysical parameters. Blood, 2011, 117, e39-e48.	1.4	363
84	The effect of balneotherapy on antioxidant, inflammatory, and metabolic indices in patients with cardiovascular risk factors (hypertension and obesity)â€"A randomised, controlled, follow-up study. Contemporary Clinical Trials, 2011, 32, 793-801.	1.8	40
85	Infection and autoimmunity: Lessons of animal models. European Journal of Microbiology and Immunology, 2011, 1, 198-207.	2.8	4
86	Synovial fluid \hat{l}^2 -endorphin level in avascular necrosis, rheumatoid arthritis, and osteoarthritis of the femoral head and knee. A controlled pilot study. Clinical Rheumatology, 2011, 30, 537-540.	2.2	12
87	Lack of evidence for association of two functional SNPs of CHI3L1 gene (HC-gp39) with rheumatoid arthritis. Rheumatology International, 2011, 31, 1003-1007.	3.0	8
88	Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cellular and Molecular Life Sciences, 2011, 68, 2667-2688.	5.4	1,719
89	Flow cytometric diagnostic assessment of cell-derived microparticles is severely confounded by immune complexes in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, A11-A12.	0.9	1
90	Specific expression of PAD4 and citrullinated proteins in lung cancer is not associated with anti-CCP antibody production. International Immunology, 2011, 23, 405-414.	4.0	27

#	Article	IF	CITATIONS
91	Increased serum PAD4 and RF in lung cancer is not associated with anti CCP antibody production. Annals of the Rheumatic Diseases, 2011, 70, A4-A4.	0.9	O
92	The effect of balneotherapy on C-reactive protein, serum cholesterol, triglyceride, total antioxidant status and HSP-60 levels. International Journal of Biometeorology, 2010, 54, 249-254.	3.0	32
93	Increased serum concentration of immune cell derived microparticles in polymyositis/dermatomyositis. Immunology Letters, 2010, 128, 124-130.	2.5	35
94	Critical role of protein glycosylation in T cell immunity/autoimmunity. Annals of the Rheumatic Diseases, 2010, 69, A71-A72.	0.9	1
95	Natural autoantibodies reactive to glycosaminoglycans are disease state markers in rheumatoid arthritis and are associated with HLA. Annals of the Rheumatic Diseases, 2010, 69, A2-A2.	0.9	1
96	C1-inhibitor autoantibodies in SLE. Lupus, 2010, 19, 634-638.	1.6	43
97	Central role of nitric oxide in the pathogenesis of rheumatoid arthritis and sysemic lupus erythematosus. Arthritis Research and Therapy, 2010, 12, 210.	3.5	132
98	Critical role of glycosylation in determining the length and structure of T cell epitopes. Immunome Research, 2009, 5, 4.	0.1	24
99	Rheumatoid arthritis and smoking: putting the pieces together. Arthritis Research and Therapy, 2009, 11, 238.	3.5	136
100	Gene expression and activity of cartilage degrading glycosidases in human rheumatoid arthritis and osteoarthritis synovial fibroblasts. Arthritis Research and Therapy, 2009, 11, R68.	3.5	37
101	Nitric oxide production of T lymphocytes is increased in rheumatoid arthritis. Immunology Letters, 2008, 118, 55-58.	2.5	50
102	Synovial glycosidases in joint diseases. Joint Bone Spine, 2008, 75, 243.	1.6	0
103	Microparticles may contribute to the pathogenesis of systemic lupus erythematosus. Joint Bone Spine, 2008, 75, 248.	1.6	0
104	Molecular mimicry and immunomodulation by the HRES-1 endogenous retrovirus in SLE. Autoimmunity, 2008, 41, 287-297.	2.6	46
105	Natural autoantibodies reactive with glycosaminoglycans in rheumatoid arthritis. Arthritis Research and Therapy, 2008, 10, R110.	3.5	27
106	IL-18 induces a marked gene expression profile change and increased Ccl1 (I-309) production in mouse mucosal mast cell homologs. International Immunology, 2008, 20, 1565-1573.	4.0	24
107	Transaldolase deficiency influences the pentose phosphate pathway, mitochondrial homoeostasis and apoptosis signal processing. Biochemical Journal, 2008, 415, 123-134.	3.7	46
108	Nitric Oxide Mediates T Cell Cytokine Production and Signal Transduction in Histidine Decarboxylase Knockout Mice. Journal of Immunology, 2007, 179, 6613-6619.	0.8	22

#	Article	IF	Citations
109	Nitric oxide differentially regulates T-cell function in rheumatoid arthritis and systemic lupus erythematosus. Arthritis Research and Therapy, 2007, 9, P26.	3.5	1
110	Histidine deficiency does not protect against aggrecan-induced arthritis. Arthritis Research and Therapy, 2007, 9, P5.	3.5	1
111	Nitric oxide, chronic inflammation and autoimmunity. Immunology Letters, 2007, 111, 1-5.	2.5	145
112	Nitric oxide, mitochondrial hyperpolarization, and T cell activation \hat{a}^{-} . Free Radical Biology and Medicine, 2007, 42, 1625-1631.	2.9	60
113	The effect of physical therapy on beta-endorphin levels. European Journal of Applied Physiology, 2007, 100, 371-382.	2.5	99
114	Simultaneous central and peripheral nervous system involvement in systemic lupus erythematosus. Ideggyogyaszati Szemle, 2007, 60, 398-402.	0.7	1
115	The role of nitric oxide in abnormal T cell signal transduction in systemic lupus erythematosus. Clinical Immunology, 2006, 118, 145-151.	3.2	15
116	Regulation of CD4 Expression via Recycling by HRES-1/RAB4 Controls Susceptibility to HIV Infection. Journal of Biological Chemistry, 2006, 281, 34574-34591.	3.4	58
117	Mitochondrial Signal Transduction Abnormalities in Systemic Lupus Erythematosus. Current Immunology Reviews, 2005, 1, 61-67.	1.2	11
118	T- and B-Cell Abnormalities in Systemic Lupus Erythematosus. Critical Reviews in Immunology, 2005, 25, 123-140.	0.5	106
119	Apoptosis and Mitochondrial Dysfunction in Lymphocytes of Patients With Systemic Lupus Erythematosus., 2004, 102, 087-114.		30
120	Nitric Oxide-Dependent Mitochondrial Biogenesis Generates Ca2+ Signaling Profile of Lupus T Cells. Journal of Immunology, 2004, 173, 3676-3683.	0.8	112
121	Mitochondrial hyperpolarization: a checkpoint of T-cell life, death and autoimmunity. Trends in Immunology, 2004, 25, 360-367.	6.8	234
122	T Cell Activation-Induced Mitochondrial Hyperpolarization Is Mediated by Ca2+- and Redox-Dependent Production of Nitric Oxide. Journal of Immunology, 2003, 171, 5188-5197.	0.8	148
123	C1r-C1s-C1inhibitor (C1rs-C1inh) complex measurements in tears of patients before and after penetrating keratoplasty. Current Eye Research, 2002, 24, 99-104.	1.5	11
124	Anticholesterol antibody levels in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2001, 60, 722-723.	0.9	3
125	Increased interferon-gamma (IFN-γ), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clinical and Experimental Immunology, 2000, 122, 464-470.	2.6	138
126	Measurement of intracellular interferon-gamma and interleukin-4 in whole blood T lymphocytes from patients with systemic lupus erythematosus. Immunology Letters, 2000, 74, 207-210.	2.5	27

#	Article	IF	CITATION
127	Usefulness of detection of complement activation products in evaluating SLE activity. Lupus, 2000, 9, 19-25.	1.6	25
128	Diagnostic value of combined evaluation of neopterin and anti-DNA antibody levels for assessment of disease activity in systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2000, 18, 699-705.	0.8	3
129	Cytoplasmic Ca2+ signalling and reduction of mitochondrial pyridine nucleotides in adrenal glomerulosa cells in response to K+, angiotensin II and vasopressin. Biochemical Journal, 1997, 322, 785-792.	3.7	52
130	Proteomic Changes of Osteoclast Differentiation in Rheumatoid and Psoriatic Arthritis Reveal Functional Differences. Frontiers in Immunology, 0, 13, .	4.8	3